Estimation of Fish and ω-3 Fatty Acid Intake in Pediatric Nonalcoholic Fatty Liver Disease

*University of Hawaii, Honolulu †Washington University, St Louis, MO ‡Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD §Columbia University, New York, NY.
Journal of pediatric gastroenterology and nutrition (Impact Factor: 2.63). 11/2013; 57(5):627-33. DOI: 10.1097/MPG.0b013e3182a1df77


Fish and ω-3 fatty acids are reported to be beneficial in pediatric nonalcoholic fatty liver disease (NAFLD), but no studies have assessed their relation to histological severity. The objectives of this study were to evaluate the dietary intake of fish and ω-3 fatty acids in children with biopsy-proven NAFLD, and examine their association with serological and histological indicators of disease.

This was a cross-sectional analysis of 223 children (6-18 years) who participated in the Treatment of Nonalcoholic Fatty Liver Disease in Children trial or the NAFLD Database study conducted by the Nonalcoholic Steatohepatitis Clinical Research Network. The distribution of fish and ω-3 fatty acid intake was determined from responses to the Block Brief 2000 Food Frequency Questionnaire, and analyzed for associations with serum alanine aminotransferase, histological features of fatty liver disease, and diagnosis of steatohepatitis after adjusting for demographic, anthropometric, and dietary variables.

The minority of subjects consumed the recommended 8 ounces of fish per week (22/223 [10%]) and 200 mg of long-chain ω-3 fatty acids per day (12/223 [5%]). Lack of fish and long-chain ω-3 fatty acid intake was associated with greater portal (P = 0.03 and P = 0.10, respectively) and lobular inflammation (P = 0.09 and P = 0.004, respectively) after controlling for potential confounders.

Fish and ω-3 fatty acid intake was insufficient in children with NAFLD, which may increase susceptibility to hepatic inflammation. Patients with pediatric NAFLD should be encouraged to consume the recommended amount of fish per week.

Download full-text


Available from: Corilee A Watters,
37 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of: Janczyk W, Socha P, Lebensztejn D et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatrics 13(23), 85-94 (2013). This article discusses the design and rationale of a randomized, multicenter, double-blind, placebo-controlled trial of omega-3 fatty acids (450-1300 mg of docosahexaenoic acid + eicosapentaenoic acid daily) for the treatment of nonalcoholic fatty liver disease (NAFLD) in children, adolescents and young adults (5-19 years of age) in comparison with placebo. The primary end point of the trial is the number of patients who experience a decrease in alanine aminotransferase activity >30% of the upper limit of normal. The main secondary end points are improvement in the biochemical liver tests, liver steatosis on ultrasound, markers of insulin resistance and difference in fat/lean body mass composition after 24 weeks of intervention. There is evidence that long-chain omega-3 fatty acids improve the lipid profile by lowering triglycerides, as well as decreasing insulin resistance and cytokine synthesis, thus tackling the mechanisms involved in the pathogenesis of NAFLD. There is evidence that long-chain omega-3 fatty acids are effective at normalizing metabolic syndrome-related aberrations, even in adolescents. Hence, long-chain omega-3 fatty acids may be a promising option for the treatment of NAFLD, even in children and adolescents. However, other aspects and measures should be considered.
    Clinical Lipidology 10/2013; 8(5):509-512. DOI:10.2217/clp.13.51 · 0.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and it has overlapping pathogenesis with diabetes and cardiovascular disease. Reviewed here are recent advances in understanding the contribution of diet and selected nutrients to NAFLD. To understand the effect of diet, the microbiome must be considered because it is the interface of diet and the liver. Early studies suggest that the characteristic of the microbiota is altered in NAFLD. Fructose is a lipogenic carbohydrate that contributes to insulin resistance, hypertriglyceridemia and appears to be associated with the severity of NAFLD. Fructose absorption and malabsorption may alter the microbiota and could be mediating effects on the liver. Lipids also have potent microbiome interactions and could contribute to the benefit of diets emphasizing lipid changes. Several new studies demonstrate that the Mediterranean diet and 'lifestyle change' are effective in modestly improving NAFLD. A new study of 'lifestyle' in children showed simultaneous improvement in cardiovascular disease risk measurements and hepatic steatosis. Current data supports limiting sugar in the diet and 'lifestyle change' as a first-line treatment for NAFLD; however, the benefits from these appear to be modest. The effects of diet on the liver are mediated through the microbiome and expansion of research in this area is needed.
    Current opinion in lipidology 12/2013; 25(1). DOI:10.1097/MOL.0000000000000043 · 5.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With increasing prevalence of childhood obesity, non-alcoholic fatty liver disease (NAFLD) has emerged as the most common cause of liver disease among children and adolescents in industrialized countries. It is generally recognized that both genetic and environmental risk factors contribute to the pathogenesis of NAFLD. Recently, there has been a growing body of evidence to implicate altered gut microbiota in the development of NAFLD through the gut-liver axis. The first line of prevention and treatment of NAFLD in children should be intensive lifestyle interventions such as changes in diet and physical activity. Recent advances have been focused on limitation of dietary fructose and supplementation of antioxidants, omega-3 fatty acids, and prebiotics/probiotics. Convincing evidences from both animal models and human studies have shown that reduction of dietary fructose and supplement of vitamin E, omega-3 fatty acids, and prebiotics/probiotics improve NAFLD.
    Nutrients 11/2014; 6(11):4691-705. DOI:10.3390/nu6114691 · 3.27 Impact Factor
Show more